经皮冠状动脉介入治疗围手术期抗栓治疗的演变  

Evolution of Antithrombotic Therapy During Perioperative Percutaneous Coronary Intervention

作　　者：金冉阳 刘德敏[1] 崔炜[1] JIN Ranyang;LIU Demin;CUI Wei(Department of Cardiology,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei,China)

机构地区：[1]河北医科大学第二医院心内科,河北石家庄050000

出　　处：《心血管病学进展》2023年第1期39-43,共5页Advances in Cardiovascular Diseases

摘　　要：自1979年Grüntzig第一个血管成形术至今,经皮冠状动脉介入治疗(PCI)已成为临床上治疗冠心病的重要方法之一。20世纪90年代初PCI围手术期抗栓治疗的出现,更是显著地降低了PCI后支架内血栓形成和支架内再狭窄等恶性事件的发生率,极大地改善了PCI患者的预后,然而随之带来的出血风险也逐渐引起了人们的重视。国际上对于PCI围手术期抗栓治疗的药物选择及应用时长等一直争论不休。现就近年国内外PCI围手术期抗栓治疗的演变进行分析,希望能为未来国内PCI围手术期抗栓治疗的应用提出一些建议。Since Grüntzig’s first angioplasty in 1979,percutaneous coronary intervention(PCI)has become one of the clinically important methods for the treatment of coronary heart disease.The emergence of antithrombotic therapy during PCI perioperative period in the early 1990s significantly reduced the incidence of malignant events such as in-stent thrombosis and in-stent restenosis after PCI,and greatly improved the prognosis of PCI patients.However,the associated bleeding risk has gradually attracted people’s attention.The choice of antithrombotic therapy during PCI perioperative period and the duration of application have been controversial.This article analyzes the evolution of antithrombotic therapy during PCI perioperative period at home and abroad in recent years,hoping to make some suggestions for the application of antithrombotic therapy during PCI perioperative period in China in the future.

关 键 词：经皮冠状动脉介入治疗 围手术期 抗栓治疗 

分 类 号：R541.4[医药卫生—心血管疾病]